PMC:7100515 / 18118-18447 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T150","span":{"begin":278,"end":285},"obj":"Body_part"},{"id":"T151","span":{"begin":289,"end":297},"obj":"Body_part"},{"id":"T152","span":{"begin":323,"end":328},"obj":"Body_part"}],"attributes":[{"id":"A150","pred":"fma_id","subj":"T150","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A151","pred":"fma_id","subj":"T151","obj":"http://purl.org/sig/ont/fma/fma63836"},{"id":"A152","pred":"fma_id","subj":"T152","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"While cathepsin B inhibitor treatment did not show any marked effect on virus entry, cathepsin L inhibition treatment decreased entry of SARS-CoV-2 S pseudovirions into 293/hACE2 by over 76% (Fig. 4a), suggesting that cathepsin L should be essential for priming of SARS-CoV-2 S protein in lysosome for entry into 293/hACE2 cells."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T144","span":{"begin":137,"end":145},"obj":"Disease"},{"id":"T145","span":{"begin":265,"end":273},"obj":"Disease"}],"attributes":[{"id":"A144","pred":"mondo_id","subj":"T144","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A145","pred":"mondo_id","subj":"T145","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"While cathepsin B inhibitor treatment did not show any marked effect on virus entry, cathepsin L inhibition treatment decreased entry of SARS-CoV-2 S pseudovirions into 293/hACE2 by over 76% (Fig. 4a), suggesting that cathepsin L should be essential for priming of SARS-CoV-2 S protein in lysosome for entry into 293/hACE2 cells."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T416","span":{"begin":16,"end":17},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T417","span":{"begin":72,"end":77},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T418","span":{"begin":169,"end":172},"obj":"http://purl.obolibrary.org/obo/CLO_0001230"},{"id":"T419","span":{"begin":169,"end":172},"obj":"http://purl.obolibrary.org/obo/CLO_0037237"},{"id":"T420","span":{"begin":169,"end":172},"obj":"http://purl.obolibrary.org/obo/CLO_0050903"},{"id":"T421","span":{"begin":169,"end":172},"obj":"http://purl.obolibrary.org/obo/CLO_0054249"},{"id":"T422","span":{"begin":169,"end":172},"obj":"http://purl.obolibrary.org/obo/CLO_0054250"},{"id":"T423","span":{"begin":169,"end":172},"obj":"http://purl.obolibrary.org/obo/CLO_0054251"},{"id":"T424","span":{"begin":169,"end":172},"obj":"http://purl.obolibrary.org/obo/CLO_0054252"},{"id":"T425","span":{"begin":289,"end":297},"obj":"http://purl.obolibrary.org/obo/GO_0005764"},{"id":"T426","span":{"begin":313,"end":316},"obj":"http://purl.obolibrary.org/obo/CLO_0001230"},{"id":"T427","span":{"begin":313,"end":316},"obj":"http://purl.obolibrary.org/obo/CLO_0037237"},{"id":"T428","span":{"begin":313,"end":316},"obj":"http://purl.obolibrary.org/obo/CLO_0050903"},{"id":"T429","span":{"begin":313,"end":316},"obj":"http://purl.obolibrary.org/obo/CLO_0054249"},{"id":"T430","span":{"begin":313,"end":316},"obj":"http://purl.obolibrary.org/obo/CLO_0054250"},{"id":"T431","span":{"begin":313,"end":316},"obj":"http://purl.obolibrary.org/obo/CLO_0054251"},{"id":"T432","span":{"begin":313,"end":316},"obj":"http://purl.obolibrary.org/obo/CLO_0054252"},{"id":"T433","span":{"begin":323,"end":328},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"While cathepsin B inhibitor treatment did not show any marked effect on virus entry, cathepsin L inhibition treatment decreased entry of SARS-CoV-2 S pseudovirions into 293/hACE2 by over 76% (Fig. 4a), suggesting that cathepsin L should be essential for priming of SARS-CoV-2 S protein in lysosome for entry into 293/hACE2 cells."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T158","span":{"begin":6,"end":27},"obj":"Chemical"},{"id":"T159","span":{"begin":18,"end":27},"obj":"Chemical"},{"id":"T160","span":{"begin":278,"end":285},"obj":"Chemical"}],"attributes":[{"id":"A158","pred":"chebi_id","subj":"T158","obj":"http://purl.obolibrary.org/obo/CHEBI_64932"},{"id":"A159","pred":"chebi_id","subj":"T159","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A160","pred":"chebi_id","subj":"T160","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"While cathepsin B inhibitor treatment did not show any marked effect on virus entry, cathepsin L inhibition treatment decreased entry of SARS-CoV-2 S pseudovirions into 293/hACE2 by over 76% (Fig. 4a), suggesting that cathepsin L should be essential for priming of SARS-CoV-2 S protein in lysosome for entry into 293/hACE2 cells."}

{"project":"LitCovid-sentences","denotations":[{"id":"T134","span":{"begin":0,"end":329},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"While cathepsin B inhibitor treatment did not show any marked effect on virus entry, cathepsin L inhibition treatment decreased entry of SARS-CoV-2 S pseudovirions into 293/hACE2 by over 76% (Fig. 4a), suggesting that cathepsin L should be essential for priming of SARS-CoV-2 S protein in lysosome for entry into 293/hACE2 cells."}

{"project":"LitCovid-PubTator","denotations":[{"id":"851","span":{"begin":6,"end":17},"obj":"Gene"},{"id":"852","span":{"begin":85,"end":96},"obj":"Gene"},{"id":"853","span":{"begin":173,"end":178},"obj":"Gene"},{"id":"854","span":{"begin":218,"end":229},"obj":"Gene"},{"id":"855","span":{"begin":317,"end":322},"obj":"Gene"},{"id":"856","span":{"begin":276,"end":277},"obj":"Gene"},{"id":"857","span":{"begin":148,"end":149},"obj":"Gene"},{"id":"865","span":{"begin":137,"end":147},"obj":"Species"},{"id":"866","span":{"begin":265,"end":275},"obj":"Species"}],"attributes":[{"id":"A851","pred":"tao:has_database_id","subj":"851","obj":"Gene:1508"},{"id":"A852","pred":"tao:has_database_id","subj":"852","obj":"Gene:1514"},{"id":"A853","pred":"tao:has_database_id","subj":"853","obj":"Gene:59272"},{"id":"A854","pred":"tao:has_database_id","subj":"854","obj":"Gene:1514"},{"id":"A855","pred":"tao:has_database_id","subj":"855","obj":"Gene:59272"},{"id":"A856","pred":"tao:has_database_id","subj":"856","obj":"Gene:43740568"},{"id":"A857","pred":"tao:has_database_id","subj":"857","obj":"Gene:43740568"},{"id":"A865","pred":"tao:has_database_id","subj":"865","obj":"Tax:2697049"},{"id":"A866","pred":"tao:has_database_id","subj":"866","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"While cathepsin B inhibitor treatment did not show any marked effect on virus entry, cathepsin L inhibition treatment decreased entry of SARS-CoV-2 S pseudovirions into 293/hACE2 by over 76% (Fig. 4a), suggesting that cathepsin L should be essential for priming of SARS-CoV-2 S protein in lysosome for entry into 293/hACE2 cells."}